GBP1 and ovarian carcinoma: Furthermore, preliminary experiments with small molecule-mediated inhibition of GBP1's association with PIM1 have demonstrated restoration of treatment sensitivity and reduction in ovarian cancer growth, showing that GBP1 is an excellent molecular target for combating TXR in tumor progression.